Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

The company is launching a clinical study of NS002, an investigational intranasal epinephrine powder intended as a needle-free alternative to EpiPen for anaphylaxis treatment. The study will compare patient self-administration with administration by a health care professional; no efficacy, safety, or commercialization results were disclosed.